SemBioSys Genetics’ Apo AI(Milano) program progress update (News-Medical-Net)

SemBioSys Genetics Inc. provided an update today on its progress on plant-produced Apo AI(Milano) in light of the Apo AI(Milano) license agreement between Pfizer Inc. and The Medicines Company, of Parsippany, New Jersey.

This entry was posted in Genetics, Human Genetics. Bookmark the permalink.

Comments are closed.